We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
SUNITINIB MSN sunitinib (as malate) 50 mg hard capsule bottle (Accelagen Pty Ltd)
Product name
SUNITINIB MSN sunitinib (as malate) 50 mg hard capsule bottle
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
136 (255 working days)
Active ingredients
Sunitinib malate
Registration type
New generic medicine
Indication
Sunitinib MSN is indicated for;
- treatment of advanced renal cell carcinoma (RCC)
- treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesilate treatment due to resistance or intolerance,
- treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic NET)